Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3537021 for Chemotherapy-Induced Nausea and Vomiting
NCT07169851Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in chemotherapy-induced nausea and vomiting (CINV) comparing LY3537021 + Antiemetic Therapies with Placebo + Antiemetic Therapies (2 arms). Primary endpoint: Complete Response in the Delayed Phase of CINV. Started Nov 2025; status: recruiting.
02
Drugs
LY3537021
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT07169851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169851.